Risk of Malignancy Index Assessment in Pre and Postmenopausal Women with Adnexal Masses: A Cross-Sectional Study

Risk of Malignancy Index Assessment in Pre and Postmenopausal Women with Adnexal Masses: A Cross-Sectional Study

Authors

  • Rozina Naurin Department of Obstetrics & Gynaecology, Corniche Hospital, Abu Dhabi - United Arab
  • Rubina Naurin Department of Obstetrics & Gynaecology, Central Park Teaching Hospital, Lahore
  • Tehmina Zafar Department of Obstetrics & Gynaecology, Central Park Teaching Hospital, Lahore
  • Sobia Zafar Services Institute of Medical Sciences, Lahore
  • Rubeena Badar Department of Obstetrics & Gynaecology, Central Park Teaching Hospital, Lahore

DOI:

https://doi.org/10.21649/akemu.v30i3.5539

Keywords:

Diagnostic accuracy, , Risk of malignancy index, benign tumor, malignant ovarian tumors, adnexal masses

Abstract

Background: Adnexal mass is a common presentation in gynecological settings. Differentiation between benign and malignant tumors is crucial for deciding the proper place and type of treatment. The RMI is considered a good and reliable tool in pre-operative differentiation of ovarian tumors, but limited work has been done on this tool in low-resource settings.

Objective: To assess the diagnostic accuracy of Risk of malignancy index in differentiating benign from malignant ovarian tumors.

Methods: This cross-sectional study was conducted in Department of Obstetrics & Gynaecology at a Teaching Hospital, Lahore. Eighty females between 30-80 years, admitted with adnexal mass in the Department of Obstetrics & Gynaecology at Central Park Teaching Hospital, Lahore from October 1st to 30th September, 2023 were enrolled. RMI was calculated and findings were compared with histopathology.

Results: Among enrolled 80 females with adnexal mass the mean age of females was 43.70 ± 8.21 years. The mean BMI was 30.60 ± 5.68 kg/m2. The mean duration of post-menopausal bleeding was 14.50 ± 6.22 months. The mean RMI of females was 212.95 ± 159.76. The Sensitivity of RMI was 100%, specificity was 90.6%, PPV was 72.7%, NPV was 100%, and diagnostic accuracy was 92.5% taking histopathological findings as gold standard.

Conclusion: Thus, RMI is found to be a reliable tool for the diagnosis of ovarian malignancy in females with suspicious adnexal mass.

References

Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer. Prz Menopauzalny. 2023;22(2):93-104. doi:10.5114/pm.2023.128661

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians. 2018 Jan;68(1):7-30.

Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. In Seminars in oncology nursing.2019;35(2):151-156. WB Saunders.

Gul S, Ishaque SM, Shehzad H, Naseem M, Khattak A, Kehar SI. Evaluating the Age Related Frequency of Borderline and Malignant Epithelial Ovarian Tumors at a Tertiary Care Hospital in Karachi. InMed Forum 2019;30(6):107-110.

Ahmad Z, Idress R, Fatima S, Uddin N, Ahmed A, Minhas K, et al. Commonest cancers in Pakistan - findings and histopathological perspective from a premier surgical pathology center in Pakistan.. Asian Pac J Cancer Prev.2016;17(3):1061-1075

Bibi S, Ashfaque S, Laghari NA. A heartrending burden of gynaecological cancers in advance stage at nuclear institute of medicine and radiotherapy Jamshoro Sindh. Pak J of Med Sci. 2016;32(1):120-124.

Manzoor H, Naheed H, Ahmad K, Iftikhar S, Asif M, Shuja J, et al. Pattern of gynaecological malignancies in south western region of Pakistan: An overview of 12 years. Biomedical reports. 2017;7(5):487-91.

Chaudhary S, Singhal SR, Latika L, Gupta A. Study of sociodemographic profile and pattern of gynaecological malignancies in a tertiary care center. Int J Reprod Contracept Obstet Gynecol. 2016;5(8):2640-4.

Khatoon F, Begum SA, Sultana Z, Nazneen T. Clinico-pathological Study of Malignant Ovarian Tumor in a Tertiary Care Hospital. Mymensingh Med J. 2022;31(4):1040-1047.

Wasim T, Mushtaq J, Wasim AZ, Raana GE. Gynecological malignancies at tertiary care hospital, Pakistan: A five-year review. Pak J of Med Sci. 2021;37(3):621-627.

Ngu SF, Chai YK, Choi KM, Leung TW, Li J, Kwok GS, et al. Diagnostic performance of Risk of Malignancy Algorithm (ROMA), Risk of Malignancy Index (RMI) and expert ultrasound assessment in a pelvic mass classified as inconclusive by International Ovarian Tumour Analysis (IOTA) simple rules. Cancers. 2022;14(3):810. https://doi.org/10.3390/cancers14030810

Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer chemotherapy and pharmacology. 2018;81(1):17-38.

Koshiyama M, Matsumura N, Konishi I. Subtypes of ovarian cancer and ovarian cancer screening. Diagnostics. 2017;7(1):12.

Mallen AR, Townsend MK, Tworoger SS. Risk factors for ovarian carcinoma. Hematology/Oncology Clinics. 2018;32(6):891-902. doi: 10.1016/j.hoc.2018.07.002.

Saini S, Srivastava S, Singh Y, Dixit A, Prasad S. Epidemiology of epithelial ovarian cancer, a single institution-based study in India. Clin Cancer Investig J. 2016;5(1):20-4. https://doi.org/10.4103/2278-0513.172078

Javdekar R, Maitra N. Risk of Malignancy Index (RMI) in Evaluation of Adnexal Mass. J of obstet Gynaecol India. 2015;65(2):117-121.

Al-Musalhi K, Al-Kindi M, Ramadhan F, Al-Rawahi T, Al-Hatali K, Mula-Abed WA. Validity of cancer antigen-125 (CA-125) and risk of malignancy index (RMI) in the diagnosis of ovarian cancer. Oman Med J. 2015;30(6):428. doi: 10.5001/omj.2015.85.

Shekar NC, Dasappa P, Rangaiah N, Nagothi NP. Evaluation of risk of Malignancy index 5-a new indicator in differentiating benign and malignant ovarian masses. J South Asian Fed Obstet Gynaecol. 2019;11(4):259-262.

Yelikar KA, Deshpande SS, Nanaware SS, Pagare SB. Evaluation of the validity of risk malignancy index in clinically diagnosed ovarian masses and to compare it with the validity of individual constituent parameter of risk malignancy index. Int J Reprod Contracept Obstet Gynecol. 2016;5(2):460-464.

Sölétormos G, Duffy MJ, Hassan SO, Verheijen RH, Tholander B, Bast RC, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers. Int J Gynecol Cancer. 2016;26(1).

Ozbay PO, Ekinci T, Çaltekin MD, Yilmaz HT, Temur M, Yilmaz O, et al. Comparative evaluation of the risk of malignancy index scoring systems (1-4) used in differential diagnosis of adnexal masses. Asian Pac J Cancer Prev. 2015;16(1):345-9.

Kaur A, Sharma S, Singh S. Role of risk of malignancy index 4 in evaluation of adnexal masses. Int J Reprod Contracept Obstet Gynecol. 2020;9(9):3819. DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20203863

Nurseta T, Harnandari DE, Herliawati PA, Nooryanto M, Handayani P. Risk Of Malignancy Index 4 Performance as a Predictor Advanced Stage Epithelial Ovarian Carcinoma Used for Neoadjuvant Chemotherapy. Medical Laboratory Technology Journal. 2021;7(2):101-11.

Dikmen ZG, Colak A, Dogan P, Tuncer S, Akbiyik F. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer. Eur J Gynaecol Oncol. 2015;36(4):457-62.

Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12(1):1-9. doi: 10.1186/s13048-019-0503-7

Moore RG, Blackman A, Miller MC, Robison K, DiSilvestro PA, Eklund EE, et al. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?. Gynecol Oncol. 2019 ;154(1):150-5.

Chirdchim W, Wanichsetakul P, Phinyo P, Patumanond J, Suwannarurk K, Srisomboon J, et al. Development and Validation of a Predictive Score for Preoperative Diagnosis of Early Stage Epithelial Ovarian Cancer. Asian Pac J Cancer Prev: APJCP. 2019;20(4):1207-1213.

Obstetricians ACo, Gynecologists. Practice bulletin no. 174: evaluation and management of adnexal masses. Obstet Gynecol. 2016;128(5):e210-e26.

NICE Clinical guideline [CG122]. nice.org.uk. [cited 02 october 2023] Cancer NCCf. Ovarian cancer: the recognition and initial management of ovarian cancer.Avaialable from https://www.nice.org.uk/guidance/cg122.

Kaijser J, Sayasneh A, Van Hoorde K, Ghaem-Maghami S, Bourne T, Timmerman D, et al. Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: A systematic review and meta-analysis. Hum Reprod Update. 2014;20(3):449-462. doi: 10.1093/humupd/dmt059.

Auekitrungrueng R, Tinnangwattana D, Tantipalakorn C, Charoenratana C, Lerthiranwong T, Wanapirak C, et al. Comparison of the diagnostic accuracy of International Ovarian Tumor Analysis simple rules and the risk of malignancy index to discriminate between benign and malignant adnexal masses. Int J Gynecol Obstet. 2019;146(3):364-369.

Shetty J, Saradha A, Pandey D, Bhat R, Kumar P, Bharatnur S, et al. IOTA simple ultrasound rules for triage of adnexal mass: Experience from South India. J Obstet Gynecol India. 2019;69(4):356-362. doi: 10.1007/s13224-019-01229-z.

Downloads

Published

09/30/2024

How to Cite

Rozina Naurin, Rubina Naurin, Tehmina Zafar, Sobia Zafar, & Rubeena Badar. (2024). Risk of Malignancy Index Assessment in Pre and Postmenopausal Women with Adnexal Masses: A Cross-Sectional Study. Annals of King Edward Medical University, 30(3), 315–321. https://doi.org/10.21649/akemu.v30i3.5539

Issue

Section

Research Articles
Loading...